Avesthagen To Launch Genetic Testing Portfolio Commercial For Cancer and Other Diseases
Avesthagen Limited, a biotechnology company, has entered into a four-year strategic alliance with Wipro to launch a genetic testing portfolio commercial. The portfolio includes a genome panel offering highly specific disease-center analysis for conditions like cancers, neurodegenerative diseases, autoimmune disorders and rare disease conditions.
Together, Avesthagen and Wipro will title the portfolio as “Cancer Risk Assessed by NGS profiling of Circulating free DNA and RNA for Lung Cancer project related Genomics Sequencing Services”.
In the joint project, Wipro, leading global information technology, consulting and business process services company, will perform the initial processing of the samples at its state-of-the-art Life Sciences lab. Along with this, it will generate data on the latest next-gen sequencing platforms, compile genomic sequences and analyze detailed molecular information using computational AI/ML-based tools.
“Genomics-based innovation is part of Avesthagen’s DNA. The Avesta Genome Project we started in 2008 is the largest epidemiological study ever conducted on a consanguineous population worldwide. The diagnostic tools portfolio we are launching today is the result of the collective knowledge we have amassed since and are looking forward to working with WIPRO to take clinical genetics-based precision diagnostics to the people,” says Dr. Villoo Morawala-Patell, Founder, Chairman and Managing Director, Avesthagen Limited.
In answer to the statement, Mr. Srikumar Rao, General Manager And Delivery Leader, Wipro Engineering,, said, “We are excited to join forces with Avesthagen Limited. This partnership will leverage our Tarang Lifesciences labs and R&D expertise, with the goal of identifying new disease-specific biomarkers, improving genomic diversity, better healthcare outcomes and smart precision therapeutics”.
As per the cancer statistics report of National Cancer Registry Programme ━ India is likely to record over one lakh cases of lung cancer in the next five years in India. Report suggests that almost half of the patients get diagnosed when cancer has already spread to other parts of the body, thus, reducing their chances of survival. This highlights the importance of the detecting disease at an early stage, which will increase the survival rate.
Previous Post: Is it safe to use pregnancy water bottle?
